U.S. Physical Therapy heads into its May 7 Q1 earnings call with options positioning at its most defensive in at least a year.
The options signal is the sharpest data point in the setup. The put/call ratio hit 5.79 on May 6 — the highest reading of the past 52 weeks, and well above its 20-day average of 3.41. That skew reflects an unusual surge in put-side demand right before the print, even after a quiet month for short sellers.
Short interest tells a calmer story. Bears have actually trimmed exposure, with SI falling roughly 6% over the past month to 6.3% of the free float — around 956,000 shares. Days to cover runs close to seven, which is moderately elevated but not extreme. Borrow costs are negligible at 0.53% APR. Availability remains comfortable, suggesting the lending market is not under meaningful pressure heading into the report. The ORTEX short score of 48.5 places USPH squarely in the middle of the universe — bears are present but not piling in.
The bull case rests on USPH's industrial injury prevention segment, which has been the fastest-growing part of the business. Management guided adjusted EBITDA of $93–$97 million for FY2025, implying roughly 8.6% growth year-on-year. Bulls also point to 2026 as the first year in several without Medicare pricing headwinds — a meaningful structural tailwind for the core outpatient therapy business. Bears counter that managed care exposure and reimbursement rate risk remain live concerns, and that competitive dynamics in outpatient therapy could cap margin expansion even as pricing pressure eases. Analysts are broadly constructive: Jefferies initiated with a Buy at $102 in March, and Barrington Research has maintained its Outperform at $103 across multiple reviews. JP Morgan trimmed its target to $100 from $110 in late November, but held its Overweight. All three targets sit materially above the current price of $73.65 — implying the stock has already de-rated significantly from where the Street set its expectations, a gap worth watching into the print.
The prior earnings release in February produced a muted 1-day gain of roughly 1.6%, with the five-day follow-through similarly subdued. Institutional ownership is dense and stable — BlackRock leads at 14.5% of shares, with Vanguard and Eaton Vance each holding above 5% and reporting only incremental changes in their most recent filings. Insider activity has skewed toward selling since mid-2025, with the COO and General Counsel both making small sales in early March, though none of the transactions approached a scale that would qualify as a directional signal. Net insider activity over the prior 90 days was a modest net buy of around 5,470 shares, driven by a November director purchase at $69.
The print will test whether USPH's revenue trajectory and EBITDA margins are tracking closely enough to justify a re-rating toward those analyst targets — or whether the gap between the $73 stock price and $100-plus consensus simply widens further.
See the live data behind this article on ORTEX.
Open USPH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
